Cancer Genetic Testing: Family History, Inherited Risk, and What Results Mean - Yenra

Gather a family history that a clinician can use

A family history is a starting point for assessment. Families share environments and habits as well as genes, so several cancer diagnoses can have more than one explanation. The CDC’s family-history guidance recommends collecting the specific cancer type and age at diagnosis for biological relatives. Include your own history, parents, siblings, children, grandparents, aunts and uncles; add other relatives when information is available.

• Record the relationship and family side. A father’s family history matters as well as a mother’s.
• Use the original cancer site if known. Write “unknown primary site” when a description such as “cancer in the liver” may refer to spread from elsewhere.
• Separate confirmed information from recollection. Note approximate ages and ask permission before seeking a relative’s report.
• Describe gaps. Adoption, a small family, early deaths or limited contact may leave history incomplete. Bring the information you have.

The NCI inherited-risk testing overview identifies reasons to discuss cancer genetics, including a known harmful family variant, cancer at a young age, several cancers in one person or patterns across relatives. A person’s own diagnosis may support testing even without a striking family history. Ask your team which current criteria apply to your cancer type and situation.

Different inherited conditions can connect different cancers. Harmful BRCA1 or BRCA2 variants can affect breast, ovarian, pancreatic and prostate cancer risk. Lynch syndrome involves colorectal, endometrial and other cancers. These examples help explain why a counselor asks about the whole family, rather than only the cancer that prompted the visit.

For the cancer-specific conversation, see breast-cancer biomarkers, ovarian-cancer inherited-risk questions, pancreatic-cancer testing, prostate-cancer care options and colorectal symptoms and personal risk.

Understand the two testing questions

The word “genetic” can appear on very different reports. Ask whether the test concerns an inherited predisposition, the cancer’s characteristics, or both. The NCI biomarker-testing explanation describes how tumor tests can help select treatment and sometimes flag a possible inherited finding.

On a small screen, scroll the table sideways. Keyboard users can focus the table region and use the arrow keys.

The sample alone does not identify the purpose: blood can be used for inherited testing or a tumor “liquid biopsy.” A tumor finding may need confirmation to establish whether it is inherited. Keep the report’s name and purpose together in your notes. For another example of why the distinction matters, see molecular and inherited testing in thyroid cancer.

Use counseling to decide what information would help

Genetic counseling is a conversation about choices, possible results and their consequences. You can discuss testing and then decide whether to proceed. The CDC’s counseling guide explains how a cancer-genetics professional can assess family history, discuss the usefulness and limits of testing, and provide support before and after results.

Ask why the proposed test fits your history. A test may examine a known family variant or a panel of several genes. The CDC testing overview for hereditary breast and ovarian cancer explains these choices and why, when feasible, testing often begins with a relative who has had a relevant cancer. If that relative is unavailable, ask how testing you would be interpreted.

• What decision could each possible result help us make?
• Is this testing for inherited risk, treatment selection, or both?
• Which genes are included, and why? What important questions could remain?
• When should results arrive, and who will explain them?
• If treatment is being planned now, could the result affect timing or choices?

Bring previous test reports, including older or consumer results. The team can assess what was actually tested before deciding whether further testing would add useful information.

Read the result together with the test’s purpose

MedlinePlus explains that interpretation depends on the test and the person’s history. An inherited-risk result can identify a predisposition; it cannot predict exactly whether or when an individual will develop cancer.

Positive: pathogenic or likely pathogenic variant

A harmful variant has been identified. Ask which risks and management options are associated with that specific gene and variant, and how your age and history affect the plan. For someone with cancer, implications may include treatment questions as well as future risk.

Negative with a known family variant

When an appropriate test excludes the specific harmful variant already identified in the family, it can provide a “true negative” for that variant. Other risk factors still belong in your screening discussion.

Negative without an established family explanation

The test may leave the family pattern unexplained. Ask what it covered and whether screening should still reflect your personal and family history. A negative result is not a universal all-clear.

Variant of uncertain significance (VUS)

The evidence is insufficient to classify the variant as harmful or harmless. Care generally follows your history and other established findings; a VUS alone should not determine risk-reducing surgery. Ask who will notify you if its classification changes.

The NCI BRCA guide’s result explanations illustrate why a known family variant, a negative result and an uncertain finding require different conversations.

For consumer testing, check the test’s scope before drawing conclusions. MedlinePlus notes that consumer tests may examine only some relevant variants. Bring the full report to a qualified professional and ask whether clinical confirmation is needed before changing care.

Ask about costs, consent and privacy before the sample

Ask for the expected out-of-pocket cost of counseling, testing and the results visit; whether prior authorization is needed; and what happens if coverage is denied. Ask separately about follow-up care costs. Record the person who gave you the estimate and its date.

Read the consent and data-use information. Ask where the report will be stored, who may access it, whether research sharing is optional and what choices you have about retained samples. These questions are especially useful when a commercial service is involved.

In the United States, the National Human Genome Research Institute explains GINA’s protections and limits. GINA addresses genetic discrimination in health insurance and covered employment, but does not cover life, disability or long-term-care insurance. Employment protections have exceptions, including the military and employers with fewer than 15 employees. State laws may add protections. Ask about rules relevant to your location and circumstances before testing.

Leave with a plan for yourself and your family

At the results visit, ask for a copy of the report and a written summary of what changes now, what stays on schedule and who coordinates follow-up. Keep screening matched to your own history. New symptoms need clinical assessment regardless of a previous genetic result.

A confirmed inherited finding can help relatives ask about their own options. The CDC’s family-conversation guidance emphasizes sharing the specific result so relatives’ clinicians can identify the appropriate test. Ask your genetics team for a family letter and which relatives would benefit from a conversation. Respect each person’s choice about learning their risk; questions about testing children should go through a genetics professional.

• Save: the laboratory report, date, interpretation and care plan.
• Assign: who arranges each referral, screening visit or family letter.
• Clarify: how to contact the service about new family diagnoses or a reclassified variant.
• Complete: the next action and its due date on your worksheet.

Open the printable two-page worksheet (PDF) or save the editable text worksheet. You can take incomplete notes to the appointment and fill in details with the care team.